Press Resease

Chemotherapy-Induced Myelosuppression Treatment Market - Global Industry Analysis

Chemotherapy-Induced Myelosuppression Treatment Market by Indication (Anaemia, Neutropenia and Thrombocytopenia); by Drug Class (Thrombopoietic Agents, Erythropoietin Stimulating Agents, Iron Supplements, Growth Factors and Others); by Route of Administration (Injectable and Oral); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2025

Published Date: 07-Nov-2019 Category: Biotechnology Report Format : PDF Pages: 126 Report Code: ZMR-5000 Status : Published

Global demand for chemotherapy-induced myelosuppression treatment market was valued at approximately USD 13.81 billion in 2018, and is expected to generate revenue of around USD 17.65 billion by end of 2025, growing at a CAGR of around 3.6% between 2018 and 2025.

Description

The report covers forecast and analysis for the chemotherapy-induced myelosuppression treatment market on a global and regional level. The study provides historic data from 2016 along with forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the chemotherapy-induced myelosuppression treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the chemotherapy-induced myelosuppression treatment market on a global as well as regional level.

In order to give the users of this report a comprehensive view on the chemotherapy-induced myelosuppression treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the chemotherapy-induced myelosuppression treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new indication launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the chemotherapy-induced myelosuppression treatment market on global and regional basis.

The study provides a crucial view on the chemotherapy-induced myelosuppression treatment by segmenting the market based on indication, route of administration, drug class, distribution channel and region. All the segments of chemotherapy-induced myelosuppression treatment market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.

Suppression of bone marrow is termed as myelosuppression. Myelosuppression leads to decreased blood cells production as a result of reduced activity of bone marrow. This may cause decrease in all types of blood cells such as red blood cells (RBCs), white blood cells (WBCs) and platelets or any one. Pancytopenia refers to decrease in all three types of blood cells. Myelosuppression is most common side effect of chemotherapy. Chemotherapy may lead to mild to severe myelosuppression. Severe myelosuppression can be fatal and needs medical attention. Various symptoms of myelosuppression include fatigue, dizziness, shortness of breath, anemia in case of decrease in red blood cells, infection such as cough, chills, fever etc. in case of decrease in white blood cells. Decrease in platelet count may lead to thrombocytopenia.

The demand for chemotherapy-induced myelosuppression treatment market is driven by availability of advanced treatment options like chemotherapy, surgeries, radiotherapy, increasing preference for chemotherapy for cancer treatment, promising drug pipelines, increasing prevalence of cancer across the globe, increasing awareness among patients, increasing healthcare expenditure and increasing disposable income, launch of cost effective biosimilars. However, loss of patent exclusivity and intense competition may hinder the market growth. Extensive drug pipeline and focus of pharmaceutical companies on development of safe and efficient chemotherapy-induced myelosuppression treatment drugs will bring new growth opportunities for market players over the forecast period.

Based on indication, global chemotherapy-induced myelosuppression treatment market is bifurcated into anaemia, neutropenia and thrombocytopenia. Neutropenia indication segment accounted for largest market share in 2018 and is expected to retain its dominance over the forecast period. Neutropenia is most common side effect resulting from myelosuppression treatment. Severity and complications of neutropenia may be fatal and thus attribute to large share. Thrombocytopenia segment will register highest growth over the forecast period.

Based on drug class market is segmented into thrombopoietic agents, erythropoietin stimulating agents, iron supplements, growth factors and others. Growth factors drug class segment held dominating market share in 2018. Whereas erythropoietin stimulating agents drug class segment will witness highest growth rate over the forecast period.

Based on route of administration, global chemotherapy-induced myelosuppression treatment market is categorized into injectable and oral. Injectable administration route segment held largest market share in 2018. This is due to their higher therapeutic availability compared to oral drugs.

The distribution channel segment of the TNF inhibitor drugs market is divided into retail pharmacies, hospital pharmacies and online pharmacies. Retail pharmacies held largest revenue share in 2018 among all distribution channels. Online pharmacies are expected to witness rapid growth in the years to come.

North America dominated the global chemotherapy-induced myelosuppression treatment market in 2018. Favorable reimbursement policies, strong commercial sales, large patient pool, presence of key players, and growing awareness are major factors driving the growth in this region. Europe was second largest regional market in terms of revenue share. Increasing prevalence of cancer, availability of developed infrastructure, and growing awareness are some of factors that boost market growth in this region. Asia Pacific region will be the rapidly growing market for chemotherapy-induced myelosuppression treatment. Economic development, increasing geriatric population base and cancer prevalence, healthcare infrastructure improvement, increasing healthcare spending and disposable income, growing awareness are important factors attributing to the rapid growth in this region. On the other hand Latin America will experience moderate growth in the coming years. Middle East and Africa will register slower growth in the years to come.

Major players in chemotherapy-induced myelosuppression treatment market are Teva Pharmaceutical Industries Ltd., Amgen Inc., Janssen Global Services, LLC, Pfizer Inc., Mylan NV, Mission Pharmacal Company, Myelo Therapeutics GmbH, Dova Pharmaceuticals, Partner Therapeutics, Inc. and Novartis AG among others.

The report segment of global chemotherapy-induced myelosuppression treatment market as follows:

Global Chemotherapy-Induced Myelosuppression Treatment Market: Indication

  • Neutropenia
  • Anaemia
  • Thrombocytopenia

Global Chemotherapy-Induced Myelosuppression Treatment Market: By Drug Class

  • Growth Factors
  • Erythropoietin Stimulating Agents
  • Thrombopoietic Agents
  • Iron Supplements
  • Others

Global Chemotherapy-Induced Myelosuppression Treatment Market: By Route of Administration

  • Oral
  • Injectable

Global Chemotherapy-Induced Myelosuppression Treatment Market: By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Chemotherapy-Induced Myelosuppression Treatment Market: By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Chemotherapy-Induced Myelosuppression Treatment Market, 2016 - 2025, (USD Million)
    • 2.2. Chemotherapy-Induced Myelosuppression Treatment Market: Snapshot
  • Chapter 3. Global Chemotherapy-Induced Myelosuppression Treatment Market – Industry Analysis
    • 3.1. Chemotherapy-Induced Myelosuppression Treatment Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Availability of advanced treatment options like chemotherapy, surgeries, radiotherapy
      • 3.2.2. Increasing preference for chemotherapy for cancer treatment
      • 3.2.3. Promising drug pipelines
      • 3.2.4. Increasing prevalence of cancer
    • 3.3. Restraints
      • 3.3.1. Loss of patent exclusivity
      • 3.3.2. Intense competition
    • 3.4. Opportunity
      • 3.4.1. Emerging Markets
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by indication segment
      • 3.6.2. Market attractiveness analysis by drug class segment
      • 3.6.3. Market attractiveness analysis by route of administration segment
      • 3.6.4. Market attractiveness analysis by distribution channel segment
      • 3.6.5. Market attractiveness analysis by regional segment
  • Chapter 4. Global Chemotherapy-Induced Myelosuppression Treatment Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global chemotherapy-induced myelosuppression treatment market: company market share analysis, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New indication launches
      • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Chemotherapy-Induced Myelosuppression Treatment Market – Indication Segment Analysis
    • 5.1. Global chemotherapy-induced myelosuppression treatment market overview: by indication
      • 5.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by indication, 2018 and 2025
    • 5.2. Neutropenia
      • 5.2.1. Global chemotherapy-induced myelosuppression treatment market by Neutropenia, 2016-2025 (USD Million)
    • 5.3. Anaemia
      • 5.3.1. Global chemotherapy-induced myelosuppression treatment market by Anaemia, 2016-2025 (USD Million)
    • 5.4. Thrombocytopenia
      • 5.4.1. Global chemotherapy-induced myelosuppression treatment market by Thrombocytopenia, 2016-2025 (USD Million)
  • Chapter 6. Global Chemotherapy-Induced Myelosuppression Treatment Market – Drug Class Segment Analysis
    • 6.1. Global chemotherapy-induced myelosuppression treatment market overview: by drug class
      • 6.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by drug class, 2018 and 2025
    • 6.2. Growth Factors
      • 6.2.1. Global chemotherapy-induced myelosuppression treatment market by Growth Factors, 2016-2025 (USD Million)
    • 6.3. Erythropoietin Stimulating Agents
      • 6.3.1. Global chemotherapy-induced myelosuppression treatment market by Erythropoietin Stimulating Agents, 2016-2025 (USD Million)
    • 6.4. Thrombopoietic Agents
      • 6.4.1. Global chemotherapy-induced myelosuppression treatment market by Thrombopoietic Agents, 2016-2025 (USD Million)
    • 6.5. Iron Supplements
      • 6.5.1. Global chemotherapy-induced myelosuppression treatment market by Iron Supplements, 2016-2025 (USD Million)
    • 6.6. Others
      • 6.6.1. Global chemotherapy-induced myelosuppression treatment market by Others, 2016-2025 (USD Million)
  • Chapter 7. Global Chemotherapy-Induced Myelosuppression Treatment Market – Route of Administration Segment Analysis
    • 7.1. Global chemotherapy-induced myelosuppression treatment market overview: by route of administration
      • 7.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by route of administration, 2018 and 2025
    • 7.2. Oral
      • 7.2.1. Global chemotherapy-induced myelosuppression treatment market by Oral, 2016-2025 (USD Million)
    • 7.3. Injectable
      • 7.3.1. Global chemotherapy-induced myelosuppression treatment market by Injectable, 2016-2025 (USD Million)
  • Chapter 8. Global Chemotherapy-Induced Myelosuppression Treatment Market – Distribution Channel Segment Analysis
    • 8.1. Global chemotherapy-induced myelosuppression treatment market overview: by distribution channel
      • 8.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by distribution channel, 2018 and 2025
    • 8.2. Hospital Pharmacies
      • 8.2.1. Global chemotherapy-induced myelosuppression treatment market by Hospital Pharmacies, 2016-2025 (USD Million)
    • 8.3. Retail Pharmacies
      • 8.3.1. Global chemotherapy-induced myelosuppression treatment market by Retail Pharmacies, 2016-2025 (USD Million)
    • 8.4. Online Pharmacies
      • 8.4.1. Global chemotherapy-induced myelosuppression treatment market by Online Pharmacies, 2016-2025 (USD Million)
  • Chapter 9. Global Chemotherapy-Induced Myelosuppression Treatment Market - Regional Analysis
    • 9.1. Global chemotherapy-induced myelosuppression treatment market overview: by region
      • 9.1.1. Global chemotherapy-induced myelosuppression treatment market revenue share, by region, 2018 and 2025
    • 9.2. North America
      • 9.2.1. North America chemotherapy-induced myelosuppression treatment market, by country, 2016-2025 (USD Million)
      • 9.2.2. North America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.2.3. North America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.2.4. North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.2.5. North America chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.2.6. The U.S.
        • 9.2.6.1. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.2.6.2. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.2.6.3. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.2.6.4. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.2.7. Rest of North America
        • 9.2.7.1. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.2.7.2. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.2.7.3. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.2.7.4. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe chemotherapy-induced myelosuppression treatment market, by country, 2016-2025 (USD Million)
      • 9.3.2. Europe chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.3.3. Europe chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.3.4. Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.3.5. Europe chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.3.6. U.K.
        • 9.3.6.1. U.K. chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.3.6.2. U.K. chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.3.6.3. U.K. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.3.6.4. U.K. chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.3.7. France
        • 9.3.7.1. France chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.3.7.2. France chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.3.7.3. France chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.3.7.4. France chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.3.8. Germany
        • 9.3.8.1. Germany chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.3.8.2. Germany chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.3.8.3. Germany chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.3.8.4. Germany chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.3.9. Rest of Europe
        • 9.3.9.1. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.3.9.2. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.3.9.3. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.3.9.4. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific chemotherapy-induced myelosuppression treatment market, by country, 2016-2025 (USD Million)
      • 9.4.2. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.4.3. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.4.4. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.4.5. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.4.6. China
        • 9.4.6.1. China chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.4.6.2. China chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.4.6.3. China chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.4.6.4. China chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.4.7. Japan
        • 9.4.7.1. Japan chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.4.7.2. Japan chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.4.7.3. Japan chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.4.7.4. Japan chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.4.8. India
        • 9.4.8.1. India chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.4.8.2. India chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.4.8.3. India chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.4.8.4. India chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.4.9. Rest of Asia Pacific
        • 9.4.9.1. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.4.9.2. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.4.9.3. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.4.9.4. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America chemotherapy-induced myelosuppression treatment market, by country, 2016-2025 (USD Million)
      • 9.5.2. Latin America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.5.3. Latin America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.5.4. Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.5.5. Latin America chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.5.6.2. Brazil chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.5.6.3. Brazil chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.5.6.4. Brazil chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
      • 9.5.7. Rest of Latin America
        • 9.5.7.1. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
        • 9.5.7.2. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
        • 9.5.7.3. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
        • 9.5.7.4. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
    • 9.6. Middle East & Africa
      • 9.6.1. Middle East & Africa chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
      • 9.6.2. Middle East & Africa chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
      • 9.6.3. Middle East & Africa chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
      • 9.6.4. Middle East & Africa chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
      • 9.6.5. Middle East & Africa chemotherapy-induced myelosuppression treatment market revenue, by distribution channel, 2016-2025 (USD Million)
  • Chapter 10. Company Profiles
    • 10.1. Teva Pharmaceutical Industries Ltd.
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product Portfolio
      • 10.1.4. Business Strategy
      • 10.1.5. Recent Developments
    • 10.2. Amgen Inc.
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Product Portfolio
      • 10.2.4. Business Strategy
      • 10.2.5. Recent Developments
    • 10.3. Janssen Global Services, LLC
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Product Portfolio
      • 10.3.4. Business Strategy
      • 10.3.5. Recent Developments
    • 10.4. Pfizer Inc.
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Product Portfolio
      • 10.4.4. Business Strategy
      • 10.4.5. Recent Developments
    • 10.5. Mylan NV
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Product Portfolio
      • 10.5.4. Business Strategy
      • 10.5.5. Recent Developments
    • 10.6. Mission Pharmacal Company
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Product Portfolio
      • 10.6.4. Business Strategy
      • 10.6.5. Recent Developments
    • 10.7. Myelo Therapeutics GmbH
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Product Portfolio
      • 10.7.4. Business Strategy
      • 10.7.5. Recent Developments
    • 10.8. Dova Pharmaceuticals
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Product Portfolio
      • 10.8.4. Business Strategy
      • 10.8.5. Recent Developments
    • 10.9. Partner Therapeutics, Inc.
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Product Portfolio
      • 10.9.4. Business Strategy
      • 10.9.5. Recent Developments
    • 10.10. Novartis AG
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Product Portfolio
      • 10.10.4. Business Strategy
      • 10.10.5. Recent Developments

List of Figures

1. Market research process
2. Market research methodology
3. Global chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
4. Porter’s five forces analysis: chemotherapy-induced myelosuppression treatment market
5. Global chemotherapy-induced myelosuppression treatment market attractiveness, by indication
6. Global chemotherapy-induced myelosuppression treatment market attractiveness, by drug class
7. Global chemotherapy-induced myelosuppression treatment market attractiveness, by route of administration
8. Global chemotherapy-induced myelosuppression treatment market attractiveness, by distribution channel
9. Global chemotherapy-induced myelosuppression treatment market revenue share, by indication, 2018 and 2025
10. Global chemotherapy-induced myelosuppression treatment market by Neutropenia, 2016-2025 (USD Million)
11. Global chemotherapy-induced myelosuppression treatment market by Anaemia, 2016-2025 (USD Million)
12. Global chemotherapy-induced myelosuppression treatment market by Thrombocytopenia, 2016-2025 (USD Million)
13. Global chemotherapy-induced myelosuppression treatment market revenue share, by drug class, 2018 and 2025
14. Global chemotherapy-induced myelosuppression treatment market by Growth Factors, 2016-2025 (USD Million)
15. Global chemotherapy-induced myelosuppression treatment market by Erythropoietin Stimulating Agents, 2016-2025 (USD Million)
16. Global chemotherapy-induced myelosuppression treatment market by Thrombopoietic Agents, 2016-2025 (USD Million)
17. Global chemotherapy-induced myelosuppression treatment market by Iron Supplements, 2016-2025 (USD Million)
18. Global chemotherapy-induced myelosuppression treatment market by Others, 2016-2025 (USD Million)
19. Global chemotherapy-induced myelosuppression treatment market revenue share, by route of administration, 2018 and 2025
20. Global chemotherapy-induced myelosuppression treatment market by Oral, 2016-2025 (USD Million)
21. Global chemotherapy-induced myelosuppression treatment market by Injectable, 2016-2025 (USD Million)
22. Global chemotherapy-induced myelosuppression treatment market revenue share, by distribution channel, 2018 and 2025
23. Global chemotherapy-induced myelosuppression treatment market by Hospital Pharmacies, 2016-2025 (USD Million)
24. Global chemotherapy-induced myelosuppression treatment market by Retail Pharmacies, 2016-2025 (USD Million)
25. Global chemotherapy-induced myelosuppression treatment market by Online Pharmacies, 2016-2025 (USD Million)
26. Global chemotherapy-induced myelosuppression treatment market revenue share, by region, 2018 & 2025
27. North America chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
28. Europe chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
29. Asia Pacific chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
30. Latin America chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
31. Middle East & Africa chemotherapy-induced myelosuppression treatment market, 2016-2025 (USD Million)
 
 


List of Tables

1. Global chemotherapy-induced myelosuppression treatment market: snapshot
2. Drivers for chemotherapy-induced myelosuppression treatment market: impact analysis
3. Restraints for chemotherapy-induced myelosuppression treatment market: impact analysis
4. North America chemotherapy-induced myelosuppression treatment market revenue, by country, 2016-2025 (USD Million)
5. North America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
6. North America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
7. North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
8. North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
9. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
10. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
11. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
12. The U.S. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
13. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
14. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
15. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
16. Rest of North America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
17. Europe chemotherapy-induced myelosuppression treatment market revenue, by country, 2016-2025 (USD Million)
18. Europe chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
19. Europe chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
20. Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
21. Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
22. U.K. chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
23. U.K. chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
24. U.K. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
25. U.K. chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
26. France chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
27. France chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
28. France chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
29. France chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
30. Germany chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
31. Germany chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
32. Germany chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
33. Germany chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
34. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
35. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
36. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
37. Rest of Europe chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
38. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by country, 2016-2025 (USD Million)
39. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
40. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
41. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
42. Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
43. China chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
44. China chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
45. China chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
46. China chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
47. Japan chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
48. Japan chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
49. Japan chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
50. Japan chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
51. India chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
52. India chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
53. India chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
54. India chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
55. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
56. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
57. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
58. Rest of Asia Pacific chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
59. Latin America chemotherapy-induced myelosuppression treatment market revenue, by country, 2016-2025 (USD Million)
60. Latin America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
61. Latin America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
62. Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
63. Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
64. Brazil chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
65. Brazil chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
66. Brazil chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
67. Brazil chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
68. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
69. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
70. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
71. Rest of Latin America chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
72. Middle  East & Africa chemotherapy-induced myelosuppression treatment market revenue, by indication, 2016-2025 (USD Million)
73. Middle  East & Africa chemotherapy-induced myelosuppression treatment market revenue, by drug class, 2016-2025 (USD Million)
74. Middle  East & Africa chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
75. Middle  East & Africa chemotherapy-induced myelosuppression treatment market revenue, by route of administration, 2016-2025 (USD Million)
 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social